Search

Displaying results 4411 - 4420 of 9333 in total
  1. Drug

    Fenbendazole

    go.drugbank.com/drugs/DB11410
    InvestigationalVet approved

    Fenbendazole is approved to be administered under veterinary to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. … It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and

  2. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients. … CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease.

  3. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract.

  4. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    not respond to Neotrofin. … AIT-034 does not induce the production of NGF, and its mechanism of action is therefore believed to be different than Neotrofin.

  5. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib is intended for the treatment of hematologic malignancies and the solid tumors. … Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels

  6. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.

  7. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  8. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    This is a novel therapeutic approach to treat kidney inflammation. … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.

  9. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  10. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … [A40018] EGFR often have mutations that lead to unfavourable treatment options and prognosis.